Business Context and Reporting Period
Company: Kitov Pharmaceuticals Holdings Ltd. (trading as Purple Biotech Ltd. in the request metadata, but identified as Kitov in the filing).
Reporting Period: Fiscal year ended December 31, 2015.
Business Overview: Kitov is a clinical-stage biopharmaceutical company incorporated in Israel. It focuses on developing fixed-dose combination drugs to simultaneously treat pain caused by osteoarthritis and hypertension. The company has no commercial revenue and relies on financing to fund research and development (R&D). Its primary therapeutic candidate, KIT-302 (celecoxib and amlodipine besylate), recently completed a Phase III clinical trial.
Key Financial Metrics
| Metric (in thousands USD) | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $2,560 | $3,192 |
| General & Administrative Expenses | $1,509 | $1,269 |
| Operating Loss | $(4,069) | $(5,181) |
| Net Loss | $(4,202) | $(5,252) |
| Cash and Cash Equivalents | $10,558 | $1,313 |
| Working Capital | $9,606 | $773 |
| Total Assets | $10,812 | $1,759 |
| Total Liabilities | $(1,383) | $(986) |
| Accumulated Deficit | $(14,054) | $(9,852) |
Capitalization: As of December 31, 2015, there were 77,755,641 ordinary shares outstanding. In November 2015, the company completed a public offering of ADSs and warrants on NASDAQ, raising approximately $13 million in gross proceeds.
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $1.3 million in 2014 to $10.6 million in 2015, driven by the November 2015 NASDAQ public offering and TASE offerings.
- Reduced Operating Loss: The net loss decreased by approximately $1.05 million (20%) compared to 2014. This was primarily due to a decrease in R&D expenses (offset by amounts receivable from a development partner) and the absence of a one-time payment of $720,000 made to a former controlling shareholder in 2014.
- Share Consolidation: Historical data for 2013 and 2014 has been restated to reflect a 1-for-13 reverse stock split completed in November 2014.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- KIT-302 Progress: The company announced in December 2015 that its Phase III clinical trial for KIT-302 successfully met the primary efficacy endpoint (reduction in blood pressure). The company plans to file a New Drug Application (NDA) with the FDA in the second half of 2016, with anticipated approval in 2017.
- KIT-301 Status: Development of the second candidate, KIT-301, is currently paused to allocate resources to KIT-302.
- Capital Requirements: Management believes current cash reserves are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant additional losses and will require substantial additional capital to complete development and commercialization of its pipeline.
Risks and Contingencies
- Going Concern: While the 2015 offering removed the immediate "going concern" qualification present in prior years, the company has a history of losses and no revenue. Future profitability depends entirely on regulatory approval and commercialization.
- Legal Proceedings: A class action lawsuit was filed in December 2015 in the Tel Aviv District Court regarding the November 2015 U.S. IPO. The claim seeks approximately NIS 16.4 million. Management believes the likelihood of incurring a financial obligation is low but cannot quantify potential exposure.
- Regulatory Risk: Despite a Special Protocol Assessment (SPA) agreement with the FDA, there is no guarantee of approval. The SPA does not bind the FDA if new safety concerns arise.
- Geopolitical Risk: As an Israeli company, operations are subject to political and military instability in the region, which could disrupt business or capital raising.
Investor Verification Checklist
- Cash Runway: Verify if the $10.6 million cash balance is sufficient to fund the NDA filing and potential Phase IV trials without further dilution.
- Class Action Status: Monitor the status of the Tel Aviv class action lawsuit and any potential settlement or judgment impacts.
- FDA NDA Timeline: Confirm the submission date of the NDA for KIT-302 in late 2016 and the FDA's review timeline.
- Contractual Obligations: Review the Development Services Agreement with Dexcel Ltd., which includes milestone payments in cash and shares, and the right of first negotiation for commercialization.
- Share Dilution: Assess the impact of outstanding warrants (public and private) and options on future share count and earnings per share.